Rivastigmine Restores 5-HT<sub>1A</sub> Receptor Levels in the Hippocampus of Olfactory Bulbectomized Mice

ISSN Print: 2169-2459
ISSN Online: 2169-2467
www.scirp.org/journal/aad
E-mail: aad@scirp.org

"Rivastigmine Restores 5-HT_1A Receptor Levels in the Hippocampus of Olfactory Bulbectomized Mice"
written by Muhammad Rashedul Islam, Shigeki Moriguchi, Hideaki Tagashira, Kohji Fukunaga,
published by Advances in Alzheimer's Disease, Vol.3 No.3, 2014

has been cited by the following article(s):

[1]	AChR is partly responsible in mice depressive-like behavior after Phosalone exposure
	2021

[2]	Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors.
	Neuropsychiatric Disease and Treatment, 2018

[3]	Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors
	Neuropsychiatric disease and treatment, 2018

[4]	Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors
	2018

[5]	Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice
	Pharmacology, 2017

[6]	Memory Improvement by Yokukansankachimpihange and Atractylenolide III in the Olfactory Bulbectomized Mice
	Advances in Alzheimer's Disease, 2016

[7]	Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases
	Molecules, 2016

[1]	Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors PLOS ONE, 2018 DOI:10.1371/journal.pone.0209250

[2]	Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice Pharmacology, 2017 DOI:10.1159/000452839

[3]	Memory Improvement by Yokukansankachimpihange and Atractylenolide III in the Olfactory Bulbectomized Mice Advances in Alzheimer's Disease, 2016 DOI:10.4236/aad.2016.52003

[4]	Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases Molecules, 2016 DOI:10.3390/molecules21091165